Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk (NYSE:NVO) and maintains a $160 price target.
August 05, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk and maintains a $160 price target.
The reiteration of an Overweight rating and a maintained price target of $160 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100